Browse News

Found 345 articles

• Celularity Appoints Geoffrey Shiu Fei Ling, M.D., Ph.D. to its Board of Directors

  9/7/2023

  Celularity Inc. today announced the appointment of Geoffrey Shiu Fei Ling, M.D., Ph.D. to its Board of Directors.

• Johnson & Johnson to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference

  8/22/2023

  Johnson & Johnson (NYSE: JNJ) will participate in the Morgan Stanley 21st Annual Global Healthcare Conference at the Sheraton New York Hotel in New York on Wednesday, September 13th.

• Dr. Ehsan Samei Ph.D. joins Imalogix as Chief Scientific Advisor

  5/9/2023

  Imalogix, an industry leader in deep learning AI for imaging, announced that world renowned radiology leader and clinical researcher Dr. Ehsan Samei has joined the Imalogix team as its Chief Scientific Advisor.

• 

  Sanofi Cleans House, Cuts Assets from Principia and Ablynx Buyouts

  4/27/2023

  The French pharma drops another BTK inhibitor program from Principia and an anti-TNFa from Ablynx.

• Johnson & Johnson Reports Q1 2023 Results

  4/18/2023

  Johnson & Johnson announced results for first-quarter 2023.

• BPGbio Announces Oncology Drug Pipeline and Prostate Cancer Biomarker Developments at AACR

  4/12/2023

  BPGbio, Inc. today announced that novel data insights from its oncology therapeutics and diagnostics portfolio will be presented at the American Association for Cancer Research (AACR) Annual Meeting in Orlando, April 14 – 19, 2023.

• Takeda Announces Candidates for Board of Directors at Upcoming Shareholders Meeting

  3/30/2023

  Takeda announced that its Board of Directors decided that it will propose a new candidate for independent external director at the 147th Ordinary Meeting of Shareholders on June 28th, 2023.

• Clinical Geneticist Dr. Reed Pyeritz Receives 2023 David L. Rimoin Lifetime Achievement Award in Medical Genetics from the ACMG Foundation for Genetic and Genomic Medicine

  3/15/2023

  Internationally acclaimed clinical geneticist Reed Pyeritz, MD, PhD, FACMG, is the recipient of the 2023 ACMG Foundation for Genetic and Genomic Medicine's David L. Rimoin Lifetime Achievement Award in Medical Genetics.

• 

  Janssen Returns Phase I NASH Candidate to Arrowhead

  2/15/2023

  Arrowhead Pharmaceuticals has gained full rights to ARO-PNPLA3, formerly JNJ-75220795, the company announced Wednesday.
• 

  John Reed Jumps Ship at Sanofi to Helm J&J's R&D

  2/14/2023

  Fresh off of his Sanofi exit, John Reed is joining Johnson & Johnson, where he will serve as executive vice president, pharmaceuticals, R&D.
• 

  Sanofi R&D Head Steps Down Ahead of Busy 2023 Schedule

  2/13/2023

  Sanofi’s global head of R&D, John Reed, is leaving his position to pursue another opportunity outside the company, the French multinational announced Monday.

• Johnson & Johnson Appoints Dr. John Reed as Executive Vice President, Pharmaceuticals, R&D

  2/13/2023

  Johnson & Johnson announced the appointment of John Reed, M.D., Ph.D., to the Company’s Executive Committee as Executive Vice President of Pharmaceuticals, R&D.

• Press Release: Sanofi announces change in R&D leadership

  2/13/2023

  Paris, February 13, 2023. Sanofi announced that Dr. John Reed, its Global Head of R&D, will be leaving the company to pursue a new opportunity outside Sanofi.

• REGENATIVE LABS PUBLISHES CASE STUDY DEMONSTRATING NEW APPLICATION OF WHARTON'S JELLY ALLOGRAFTS IN POST-SURGICAL BREAST REDUCTION CARE

  1/9/2023

  Regenative Labs (Regenative), a leading HCT/P manufacturer has published a case study in the Journal of Biomedical Research and Environmental Sciences alongside Dr. Alan Meglin, of Advanced Regenerative Therapy in Georgia.

• REGENATIVE LABS ANNOUNCES CARE ADVANCEMENTS USING WHARTON'S JELLY ALLOGRAFTS IN POST-SURGICAL BREAST REDUCTION

  12/12/2022

  Regenative Labs announces advancements in breast reduction post-surgical complication care.

• Ratio Therapeutics Appoints Reed Malleck as Chief Financial Officer

  12/6/2022

  Ratio Therapeutics Inc. today announced the appointment of Reed Malleck as the company's Chief Financial Officer (CFO).

• Salarius Pharmaceuticals Announces Interim Results from Phase 1/2 Trial of Seclidemstat as a Treatment for Ewing Sarcoma and FET-Rearranged Sarcomas

  12/1/2022

  Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using targeted protein inhibition and targeted protein degradation to develop therapies for patients with cancer in need of new treatment options, announces interim clinical trial results from the company’s Phase 1/2 trial of its novel oral, reversible, targeted LSD1 inhibitor, seclidemstat, as a treatment for Ewing sarcoma and FET-rearranged sarcomas.

• Freedom Biosciences Appoints Dr. David Hough as Chief Medical Officer

  11/16/2022

  Freedom Biosciences today announced the appointment of David Hough, MD, as Chief Medical Officer.

• Hoth Therapeutics Announces Partnership with Altasciences for Manufacturing HT-TBI for Traumatic Brain Injury and Stroke

  9/20/2022

  Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced it has signed an agreement with Altasciences, a fully integrated early phase CRO/CDMO, to develop and manufacture the HT-TBI drug product formulation.

• 

  Phase III Flop Ends Sanofi's SERD Breast Cancer Candidate

  8/17/2022

  ​​​​​​​All other ongoing and pending studies of Sanofi's amcenestrant, including the early-stage breast cancer trial AMEERA-6, will also be discontinued.